Pathology informatics selected abstracts
April 2026—Technical considerations during validation of Genius digital diagnostic system; Applicability of accreditation requirements to machine learning-based methods in molecular oncology testing
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Abstracts
Clinical pathology selected abstracts
March 2026—Continuous glucose monitoring is recommended for type 1 and type 2 diabetes patients, particularly those using insulin.
Anatomic pathology selected abstracts
March 2026—A study developed an AI-based system, ATLS-8, to quantify CD8+ tumor-infiltrating lymphocytes and assess their prognostic value in hepatocellular carcinoma patients undergoing liver resection.
Molecular pathology selected abstracts
March 2026—A study at UPHS and MGB found racial and socioeconomic disparities in access to genetic evaluation.
Clinical pathology selected abstracts
February 2026—A study of 42 thrombocytopenic neonates found that platelet transfusions increased platelet counts but did not significantly impact bleeding. Another study investigated the impact of probiotics on gut microbiota after colonoscopy.
Anatomic pathology selected abstracts
February 2026—A study introduced a computational framework to analyze collagen disorder architectural (CoDA) features in colon cancer patients, revealing significant associations with clinical, molecular, and genetic factors. Additionally, a dedicated histopathologic assessment of rituximab-associated CVID-like enteropathy highlighted key histologic features, emphasizing the importance of pathologist awareness of this entity.
Molecular pathology selected abstracts
February 2026—A study of 830 children with pediatric central nervous system tumors found that 23.3% carried germline pathogenic variants in cancer predisposition genes, impacting tumor development and outcomes. Another study identified pathogenic variants in 13.2% of infertile women experiencing IVF/ICSI failures, with TUBB8 being the most frequently mutated gene.
Clinical pathology selected abstracts
January 2026—Federally qualified health centers (FQHCs) in Illinois demonstrated higher guideline adherence for kidney disease testing compared to non-FQHCs. Patients with low eGFR or diabetes at FQHCs were more likely to receive recommended uACR and dual testing, respectively.
Anatomic pathology selected abstracts
January 2026—Ossifying fibromyxoid tumors with lipomatous and cartilaginous differentiation are rare mesenchymal neoplasms that can be challenging to diagnose. A study identified six cases with these features, expanding the tumor’s known histomorphological spectrum.
Pathology informatics selected abstracts
January 2025—TITAN, a multimodal whole slide foundation model, outperforms existing slide encoders in various diagnostic and prognostic tasks, including rare disease classification. While promising, TITAN’s limitations, such as partial image representation and domain shift, necessitate further validation and workflow integration before clinical use.